EL7.AI
StocksMediumUpdated×2•Originally published 16 April 2026•Updated 17 April 2026•
1 min read

Nektar Therapeutics Nears Key Data Release for REZPEG Alopecia Treatment

Key Facts

1Key 52-week maintenance data for REZPEG in Alopecia Areata (AA) is expected before the end of April.
2Analyst models project a probability-adjusted 28% of patients reaching SALT 20 (80% or more scalp coverage).

Nektar Therapeutics is approaching a major clinical milestone with the expected release of 52-week maintenance data for its drug REZPEG before the end of April. This upcoming readout is critical for assessing the long-term efficacy of the treatment for Alopecia Areata. Analyst models currently project that approximately 28% of patients may reach the SALT 20 benchmark, representing 80% or more scalp coverage. The data release is viewed as a decisive moment for the company's commercial viability within the competitive dermatology market. Investors are closely monitoring these developments, as positive clinical outcomes often drive speculative interest in biotech equities. The results will likely dictate the near-term trajectory for NKTR stock as it seeks to solidify its position in the sector.